Pancreatic lipase inhibitors, which can make pancreatic lipase lose part of the decomposition ability and thereby reduce the accumulation of fatty acids in the body, are considered as one class of effective anti-obesity agents [3]. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.